OpenArc Corporate Advisory’s iShares Biotechnology ETF IBB Stock Holding History

OpenArc Corporate Advisory’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$760K	Sell	3,996 -34	-0.8%	-$5.84K	0.01%	393
2026 Q1	$680K	Buy	4,030 +347	+9%	+$59.3K	0.01%	382
2025 Q4	$622K	Buy	+3,683	New	+$598K	0.01%	359

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

OpenArc Corporate Advisory's IBB Position: Q2 2026 in Review

OpenArc Corporate Advisory reduced its iShares Biotechnology ETF (IBB) stake by 0.84% in Q2 2026, selling an estimated $5.84K and leaving 3,996 shares worth $760K. The position accounts for 0.01% of the portfolio, ranked #393.

OpenArc Corporate Advisory first reported a position in IBB in Q4 2025 and has held it in 3 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

OpenArc Corporate Advisory held 3,996 shares of iShares Biotechnology ETF worth $760K as of Q2 2026.
OpenArc Corporate Advisory sold 34 iShares Biotechnology ETF shares in Q2 2026, an estimated $5.84K.
iShares Biotechnology ETF made up 0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #393 holding.
OpenArc Corporate Advisory first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 3 quarters since.
960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.